LYCOS RETRIEVER 
Zyprexa: Eli Lilly
built 670 days ago
Approved in 1996, Zyprexa was so popular because of its ability to have a lower incidence of side effects than the older antipsychotics introduced in the 1950s. A 2002 Duke University study showed a connection between Zyprexa and diabetes, documenting nearly 300 cases of diabetes among Zyprexa users. Both the British Medical Control Agency and the Japanese Health and Welfare Ministry have warned about the risk of diabetes in Zyprexa patients and the FDA first requested Eli Lilly and Co. update its Zyprexa product labeling to include warning about hyperglycemia and diabetes in 2003.
Source:
"Zyprexa dominated the schizophrenia market just two years ago; ... recent focus on the drug's risk of weight gain and diabetes has changed physician perception of this agent," said Sandra Chow, analyst at Decision Resources." With the launch of new formulations and line extensions over the next two years, such as AstraZeneca's Seroquel XR, Wyeth/Solvay Pharmaceutical's bifeprunox, Janssen's paliperidone depot, and Eli Lilly's olanzapine depot, as well as the expiration of Janssen's Risperdal patent protection in 2008, the landscape of schizophrenia is poised for even greater changes."
Source:
In February 2004 Eli Lilly and Co. warned doctors that its schizophrenia treatment Zyprexa, dramatically raises the risk of death and stroke in elderly patients suffering from dementia. Approximately 3.5 percent of elderly patients with dementia taking Zyprexa died of all causes, more than twice the death rate of 1.5 percent seen among those taking placebos. Eli Lilly sold approximately $4.5 billion worth of Zyprexa in 2003.
Source:
Zyprexa is an atypical antipsychotic drug created by Eli Lilly and Co. to combat the suffering of people who suffer from schizophrenia. Unfortunately, Zyprexa is linked to a number of serious and potentially life-threatening side effects including diabetes and other blood sugar-related disorders. Also, Zyprexa was linked to the deaths of several elderly patients who used the drug to treat senile dementia.
Source:
In February of 2004, Zyprexa drug maker, Eli Lilly and Company, notified doctors and psychiatrists that elderly patients with dementia face an increased risk of stroke with Zyprexa treatment. While not approved for use in elderly dementia patients, or for anxiety or depression, physicians still prescribe the drug on an “off-label” basis. Off-label use refers to the practice of marketing or prescribing a drug in a different dose, for a longer period of time, or for a different medical condition than approved by the FDA.
Source:
Despite evidence that Zyprexa is linked to an increased risk of suicidality, Eli Lilly is not pulling its drug from the market, arguing that Zyprexa's benefits outweigh any risks. Victims who have attempted suicide and families of patients who committed suicide are now investigating the possibility of a class action lawsuit against Lilly, alleging the company did not properly warn consumers about the risks associated with Zyprexa. [MORE: ZYPREXA, SUICIDE, & AKASTHISIA]
Source:
MORE ABOUT
Eli Lilly